|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
|---|---|
| Information provided by: | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| ClinicalTrials.gov Identifier: | NCT00392756 |
Purpose
The purpose of the study is to examine how Kallmann syndrome (KS) and idiopathic hypogonadotropic hypogonadism (IHH) affect reproductive hormones. These disorders are caused by a defect in Gonadotropin Releasing Hormone (GnRH) secretion. GnRH is a hormone released by a small gland in the brain called the hypothalamus. When GnRH is released, it signals another gland in the brain, the pituitary, to secrete the reproductive hormones that influence testosterone levels and sperm production.
This study involves a detailed evaluation and an overnight stay at the hospital.
In this study, males ages 16 and older with IHH have a detailed evaluation which involves an overnight study at the hospital. Some men (18 years and older) may continue on to receive treatment with pulsatile GnRH. This treatment replaces the hormone which is absent in IHH and results in normalized testosterone and typically is effective in developing fertility.
| Condition | Intervention |
|---|---|
|
Kallmann Syndrome Hypogonadotropic Hypogonadism |
Drug: gonadotropin releasing hormone (GnRH) |
| Study Type: | Interventional |
| Study Design: | Diagnostic, Non-Randomized, Open Label, Historical Control, Single Group Assignment |
| Official Title: | Role of Gonadotropin Pulsations in the Reversal of Hypogonadotropic Hypogonadism |
| Estimated Enrollment: | 800 |
| Study Start Date: | April 1989 |
| Estimated Study Completion Date: | October 2012 |
| Estimated Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
off treatment: No Intervention
Subjects undergo the baseline evaluation off treatment
|
|
|
GnRH Treatment: Experimental
Subjects receive long term pulsatile GnRH therapy
|
Drug: gonadotropin releasing hormone (GnRH)
pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum tesosterone levels are achieved.
|
The specific aims of this study are:
Despite variability in the triggers, timing, and pace of sexual maturity between species, all species utilize the final pathway of hypothalamic secretion of GnRH to initiate and maintain the reproductive axis. Thus, GnRH is required for reproductive competence in the human. The classic studies of Knobil and his colleagues in the 1970s clearly demonstrated that pulsatile release of GnRH from the hypothalamus is a prerequisite for physiologic gonadotrope function, with continuous stimulation resulting in a paradoxical decrease in gonadotrope responsiveness.
Absence, decreased frequency or decreased amplitude of pulsatile GnRH release results in the clinical syndrome of hypogonadotropic hypogonadism (HH). Deficient GnRH secretion may occur in isolation (idiopathic hypogonadotropic hypogonadism [IHH]), in association with anosmia (Kallmann syndrome [KS]) or as a result of a variety of structural and functional lesions of the hypothalamic-pituitary axis. The phenotypic expression of GnRH deficiency in the human demonstrates considerable heterogeneity, suggesting that patients with IHH and KS may represent part of a spectrum of isolated GnRH deficiency as opposed to representing discrete diagnostic subsets.
Defining the physiology of GnRH is critical to understanding the clinical heterogeneity of isolated GnRH deficiency. This protocol will utilize the disease model of HH to increase our understanding of the physiology of GnRH secretion. Examining the baseline characteristics of patients with isolated GnRH deficiency allows the determination of the normal requirements for endogenous GnRH secretion in the human.
Recent studies have revealed an association between hyperinsulinemia and low testosterone levels in men. This finding has been demonstrated in normal physiological conditions as well as in insulin resistant states. However, the causal nature and directionality of this relationship is not yet understood. Specifically, do lower testosterone levels cause insulin resistance resulting in hyperinsulinemia or vice versa. Because insulin resistance is an important risk factor for cardiovascular disease as well as type 2 diabetes, it is important to investigate this relationship for the implications it may have for prevention of and therapeutic interventions for these disorders.
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Eligibility
Ages Eligible for Study:
Adults (18 years and older)
Male and Female
Criteria
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Andrew Dwyer, RN, FNP | 617-726-8622 | Adwyer@partners.org |
| United States, Massachusetts | |
| Massachusetts General Hospital | Recruiting |
| Boston, Massachusetts, United States, 02114-2696 | |
| Contact: Andrew Dwyer, RN, FNP 617-726-8622 Adwyer@partners.org | |
| Principal Investigator: William Crowley, MD | |
| Principal Investigator: | William F Crowley, Jr., MD | Massachusetts General Hospital/Harvard Medical School |
More Information
| Responsible Party: | MGH ( William F. Crowley Jr., MD ) |
| Study ID Numbers: | 1999-p-003752, 5U54 HD028138 |
| Study First Received: | October 25, 2006 |
| Last Updated: | October 22, 2009 |
| ClinicalTrials.gov Identifier: | NCT00392756 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Kallmann Syndrome Hypogonadotropic Hypogonadism Pulsatile GnRH |
|
Urogenital Abnormalities Pathologic Processes Disease Hypogonadism Genetic Diseases, Inborn Gonadal Disorders |
Syndrome Endocrine System Diseases Kallmann Syndrome Congenital Abnormalities Sex Differentiation Disorders |